PDCD1 binds PDCD1 inhibitors

Stable Identifier
Reaction [binding]
Homo sapiens
Locations in the PathwayBrowser
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
Programmed cell death protein 1 (PDCD1, PD-1) is an immune checkpoint protein that guards against autoimmunity. It is a cell-surface protein expressed on T cells and pro-B cells. PDCD1 inhibitors are a group of checkpoint inhibitor drugs that block the activity of PDCD1 present on the surface of these cells. They are mainly used in the treatment of various cancers.

Cemiplimab (Libtayo, REGN-2810) is the first FDA approval of a drug specifically for the treatment of advanced cutaneous squamous cell carcinoma (CSCC) (Burova et al. 2017, Migden et al. 2018). Nivolumab (Opdivo) is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor 1 (PD1) (Tan et al. 2017) indicated for many cancers (Yaghoubi et al. 2019). Camrelizumab (SHR-1210) is a fully human anti-programmed cell death 1 (PD1) monoclonal antibody being developed as an immuno-oncology therapeutic (Markham & Keam 2019).

Clinical efficacy of camrelizumab plus thymosin in patients with COVID-19 is evaluated in clinical trial NCT04268537.
Literature References
PubMed ID Title Journal Year
31313098 Camrelizumab: First Global Approval

Keam, SJ, Markham, A

Drugs 2019
23302904 Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer

Chiappori, AA, Gray, JE, Hall, RD

Cancer Control 2013
28165004 An unexpected N-terminal loop in PD-1 dominates binding by nivolumab

Tan, S, Gao, GF, Tong, Z, Wong, G, Shi, Y, Qi, J, Zhang, H, Liu, WJ, Chai, Y, Wang, Z, Song, H, Gao, S, Yan, J, Zhu, X, Yang, F, Wang, Q

Nat Commun 2017
29863979 PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

Gao, B, Lewis, KD, Babiker, HM, Papadopoulos, KP, Brana, I, Migden, MR, Dunn, LA, Yancopoulos, GD, Moreno, V, Rabinowits, G, Schadendorf, D, Niu, J, Lim, AM, Gil-Martin, M, Seebach, F, Hernandez-Aya, L, Hughes, BGM, Guminski, A, Chung, CH, Khushalani, NI, Lowy, I, Modi, B, Rischin, D, Li, J, Johnson, ML, Schmults, CD, Stankevich, E, Mathias, M, Booth, J, Thai, AA, Homsi, J, Mohan, K, Hauschild, A, Fury, MG, Chang, ALS, Owonikoko, TK, Li, S

N. Engl. J. Med. 2018
28265006 Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice

Murphy, A, D'Orvilliers, A, Woodruff, A, Garnova, E, Kantrowitz, J, Hermann, A, Rafique, A, Skokos, D, Mohrs, M, MacDonald, D, Wu, Q, Huang, T, Potocky, T, Liu, M, Thurston, G, Hong, S, Popke, J, Poueymirou, W, Allbritton, O, Olson, W, Ioffe, E, Waite, J, Lowy, I, Martin, J, Lai, V, Burova, E

Mol. Cancer Ther. 2017
30522017 PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer

Ghazvini, K, Yaghoubi, N, Soltani, A, Hashemy, SI, Hassanian, SM

Biomed. Pharmacother. 2019
21154117 Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer

Kline, J, Gajewski, TF

Curr Opin Investig Drugs 2010
Orthologous Events
Cite Us!